Apolipoprotein E and Alzheimer's disease

被引:41
|
作者
Troutwine, Benjamin R. [1 ,2 ]
Hamid, Laylan [2 ]
Lysaker, Colton R. [2 ,3 ]
Strope, Taylor A. [2 ,3 ]
Wilkins, Heather M. [1 ,2 ,3 ]
机构
[1] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA
[2] Univ Kansas, Alzheimers Dis Ctr, Kansas City, KS 66160 USA
[3] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA
基金
美国国家卫生研究院;
关键词
Apolipoprotein E; Alzheimer's disease; Mitochondria; Neuroinflammation; Amyloid beta; Tau; AMYLOID-BETA-PEPTIDE; ISOFORM-DEPENDENT MANNER; APOE EPSILON-4 ALLELE; E POLYMORPHISM; E GENOTYPE; CYTOCHROME-OXIDASE; NEURITE OUTGROWTH; MOUSE MODEL; LIPOPROTEIN RECEPTORS; POSTERIOR CINGULATE;
D O I
10.1016/j.apsb.2021.10.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Genetic variation in apolipoprotein E (APOE) influences Alzheimer's disease (AD) risk. APOE epsilon 4 alleles are the strongest genetic risk factor for late onset sporadic AD. The AD risk is dose dependent, as those carrying one APOE epsilon 4 allele have a 2-3-fold increased risk, while those carrying two epsilon 4 alleles have a 10-15-fold increased risk. Individuals carrying APOE epsilon 2 alleles have lower AD risk and those carrying APOE epsilon 3 alleles have neutral risk. APOE is a lipoprotein which functions in lipid transport, metabolism, and inflammatory modulation. Isoform specific effects of APOE within the brain include alterations to A beta, tau, neuroinflammation, and metabolism. Here we review the association of APOE with AD, the APOE isoform specific effects within brain and periphery, and potential therapeutics. (c) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:496 / 510
页数:15
相关论文
共 50 条
  • [1] Apolipoprotein E and Alzheimer's disease
    Benjamin R.Troutwine
    Laylan Hamid
    Colton R.Lysaker
    Taylor A.Strope
    Heather M.Wilkins
    [J]. Acta Pharmaceutica Sinica B, 2022, 12 (02) : 496 - 510
  • [2] Apolipoprotein E and Alzheimer's disease
    Strittmatter, WJ
    Roses, AD
    [J]. ANNUAL REVIEW OF NEUROSCIENCE, 1996, 19 : 53 - 77
  • [3] Apolipoprotein E and Alzheimer's disease
    Stephens, D
    [J]. JOURNAL OF THE ROYAL SOCIETY OF HEALTH, 1996, 116 (01): : 41 - 43
  • [4] Apolipoprotein E and Alzheimer's disease
    Strittmatter, WJ
    [J]. ALZEHEIMER'S DISEASE: A COMPENDIUM OF CURRENT THEORIES, 2000, 924 : 91 - 92
  • [5] Apolipoprotein E and survival in Alzheimer's disease
    Rocca, WA
    Waring, SC
    Tangalos, EG
    Kokmen, E
    Petersen, RC
    [J]. NEUROLOGY, 1996, 46 (02) : 55003 - 55003
  • [6] Apolipoprotein E genotyping in Alzheimer's disease
    Relkin, NR
    Tanzi, R
    Breitner, J
    Farrer, L
    Gandy, S
    Haines, J
    Hyman, B
    Mullan, M
    Poirer, J
    Strittmatter, W
    Folstein, M
    Farlow, M
    Mayeux, R
    Petersen, R
    Roses, A
    Schenk, D
    Small, G
    VanGool, W
    CookDeegan, R
    Fleck, L
    Kapp, M
    Karlinsky, H
    PericakVance, M
    Post, S
    Wolpert, C
    Berg, L
    Blass, J
    Fletcher, J
    Hegele, R
    Khachaturian, Z
    Selkoe, D
    Thal, L
    Whitehouse, P
    Kwon, YG
    [J]. LANCET, 1996, 347 (9008): : 1091 - 1095
  • [7] The Role of Apolipoprotein E in Alzheimer's Disease
    Kim, Jungsu
    Basak, Jacob M.
    Holtzman, David M.
    [J]. NEURON, 2009, 63 (03) : 287 - 303
  • [8] Alzheimer's disease and apolipoprotein E in Italy
    Sorbi, S
    Nacmias, B
    Forleo, P
    Piacentini, S
    Amaducci, L
    [J]. NEUROBIOLOGY OF ALZHEIMER'S DISEASE, 1996, 777 : 260 - 265
  • [9] Role of apolipoprotein E in Alzheimer's disease
    Zannis, VI
    Zanni, EE
    Makrides, SC
    Kardassis, D
    Aleshkov, S
    [J]. VASCULAR ENDOTHELIUM: PHARMACOLOGIC AND GENETIC MANIPULATIONS, 1998, 294 : 179 - 209
  • [10] Apolipoprotein E and the cost of Alzheimer's disease
    Frisoni, GB
    Bianchetti, A
    Trabucchi, M
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 1997, 12 (05) : 588 - 589